Tiphaine Delaunay, et al. Molecular Therapy Oncolytics, September 2020 – Read the article and view videos Publication
Category: dates
Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
20200916 Results H1 2020 EN
Transgene Announces Upcoming Investor Meetings
20200909 Next investor events
Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
20200908 Transgene TG6002 Phase 1 EN
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
Jérémy Béguin, et al. Molecular Therapy Oncolytics, September 2020 – Read the article Publication
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al. BMC Vet Res., August 25 2020 – Read the article Publication
Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
20200804 Transgene – Partial sale Tasly Shares EN
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
CP TG4001+avelumab EN – Vdef-
Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
20200709 PR Hypertrust Transgene EN
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation